

EPITHELIAL SODIUM CHANNELS IN THE ADULT LUNG – IMPORTANT MODULATORS OF PULMONARY HEALTH AND DISEASE

Ian C. Davis¹ and Sadis Matalon²

¹*Department of Veterinary Biosciences, The Ohio State University, Columbus, Ohio, USA,*
and ²*Departments of Anesthesiology & Physiology, University of Alabama, Birmingham,*
Alabama, USA.

Abstract: Absorption of excess fluid from the airways and alveolar lumen requires active vectorial transepithelial transport of sodium ions (Na⁺) by alveolar type II and possibly type I cells. The rate-limiting step in this process is the activity of the heterotrimeric apical membrane epithelial Na⁺ channel (ENaC). Pharmacologic inhibitors and genetic manipulations that disrupt Na⁺ transport result in fluid accumulation within the lung and failure of gas exchange. The importance of Na⁺ transport in the lung is also demonstrated in conditions such as ARDS, where abnormal absorption of Na⁺ contributes to the pathophysiology of pulmonary disease. ENaC expression and function is influenced by diverse factors, such as oxygen tension, glucocorticoids, and cytoskeletal proteins. In addition, ENaC dysfunction has been shown to be induced by purinergic nucleotide activation of P2Y receptors (in paramyxoviral bronchiolitis) and reactive species (in acute lung injury). Finally, β-adrenergic agonists have been shown experimentally to reverse defects in ENaC function, and improve hypoxemia and pulmonary edema, and may provide a novel therapeutic modality for ARDS, although some viral lung pathogens appear to induce insensitivity to their actions.

Key Words: respiratory virus, β-adrenergic agonist, P2Y receptor, protein kinase C

THE ROLE OF SODIUM CHANNELS IN LUNG PHYSIOLOGY

For gas exchange to occur, the epithelium of the lung must maintain a humidified atmosphere with only a thin layer of fluid lining the airway surface. Absorption of fluid out of the airway and alveolar lumen requires active transport of sodium ions (Na⁺) from the apical surface of the pulmonary epithelium, across the apical and basolateral membranes of epithelial cells, and into the interstitial space and/or bloodstream. Pharmacologic inhibitors and genetic manipulations that disrupt Na⁺ transport result in fluid accumulation within the lung and failure of gas exchange. The importance of Na⁺ transport in the lung is also demonstrated in several human disease processes, where

abnormal absorption of Na^+ contributes to the pathophysiology of pulmonary disease.

While type I alveolar pneumocytes line >95% of the distal lung surface, alveolar type II pneumocytes (ATII cells) may mediate most of the ion and fluid transport (52). ATII cells, which make up 67% of the total number of alveolar epithelial cells, can be isolated with high purity, and grown as confluent monolayers (19; 51). Electrophysiological studies of cultured ATII cells have identified apical plasma membrane cation channels, referred to as epithelial Na^+ channels (ENaC; reviewed in (53)). These channels have a higher permeability to Na^+ than other cations and can be blocked by the diuretic drug amiloride (4). Na^+ ions diffuse passively into ATII cells (and possibly ATI cells, which have been shown to express ENaC subunit proteins and to transport Na^+ ions in vitro (7; 38)) through these apical cation channels (36; 76; 76) and are extruded across the basolateral membranes by the ouabain-sensitive Na^+, K^+ -ATPase (20). While the driving force for Na^+ transport is produced by the basolateral Na^+, K^+ -ATPase, it is the apical entry of Na^+ ions through ENaC which is the rate-limiting step for Na^+ flux. Indeed, the apical plasma membrane ENaC channels offer more than 90% of the overall resistance to transepithelial Na^+ transport.

The expression and function of ENaC is highly regulated. Multiple hormones and signaling pathways influence not only expression of the channels, but also post-translational modifications that regulate channel function. By understanding Na^+ transport at the molecular level, we can better understand the molecular pathogenesis of lung disease and design more appropriate therapies and interventions.

Biology of ENaC in the lung

ENaC is a heterotrimer of 3 transmembrane subunits (α , β , and γ), which are expressed in unequal proportions in respiratory epithelia (12), although the exact stoichiometry remains controversial. Some studies have indicated that ENaC forms a tetrameric complex (2α , β , γ) (21), while others have provided data indicating that the ENaC channel is a much larger complex (3α , 3β , 3γ) (68). mRNA for all 3 subunits of ENaC is present in the lungs of both humans and mice (10), but the Na^+ channels identified to date in airway epithelia display variable biophysical characteristics (single-channel conductance, $P_{\text{Na}}/P_{\text{K}}$, and affinity for amiloride and its ethylisopropyl analog (53)). For example, expression of α , β , and γ ENaC in *Xenopus* oocytes is associated with formation of highly Na^+ selective cation channels (12), but in ATII cells both nonselective and highly Na^+ selective cation channels have been identified (76). It appears that α ENaC is sufficient to form functional amiloride-sensitive NSC channels, but the presence of β and γ subunits significantly enhances channel activity and substantively changes gating characteristics of the channel to the HSC form (12; 34; 36).

ENaC channels are constitutively open at the plasma membrane and do not appear to require additional activation (12). However, factors that influence both ENaC mRNA and protein levels can potentially modulate amiloride-sensitive Na^+ transport in the lung. Second messengers and signaling molecules may be able to alter the open probability of ENaC either by direct modification (phosphorylation/dephosphorylation) or by altering protein-protein interactions. While ENaC expression and function is known to be influenced by diverse factors, such as oxygen tension (62), glucocorticoids (73), and cytoskeletal proteins (5; 64), this review will concentrate upon three systems which

we have found to be involved in the pathogenesis of ENaC dysfunction in adult lung disease: the purinergic nucleotide system, reactive species, and β -adrenergic/cAMP agonists.

ENaC in adult lung disease

Na⁺ transport appears to be essential for maintenance of a normal gas diffusion distance in the adult lung. In adults with acute respiratory distress syndrome (ARDS), Matthay and Wiener-Kronish (54) found a positive correlation between the ability of the alveolar epithelium to transport Na⁺ actively and the rate of resolution of non-cardiogenic pulmonary edema. Similarly, instillation of the epithelial Na⁺ channel blocker phenamil into the lungs of rats exposed to hyperoxia resulted in higher levels of extravascular lung fluid volumes 24 hours later (75). Interestingly, the venom of a South American scorpion (*Tityus serrulatus*), which causes fatal respiratory failure and pulmonary edema, also decreases lung liquid clearance, probably by downregulating Na⁺,K⁺-ATPase in the alveolar epithelium (13). Finally, patients with systemic pseudohypoaldosteronism, caused by loss of function mutations in the genes encoding ENaC subunits, completely lack electrogenic Na⁺ transport in the upper and lower airways. In some cases, pseudohypoaldosteronism results in a doubling of ALF volume, persistent rhinorrhea, and recurrent respiratory illness (39).

Effect of pulmonary pathogens on Na⁺ transport

Despite the fact that fluid and mucus accumulation in airways and lung tissue is a major component of most respiratory infections (48), the effect of pathogens on respiratory epithelial Na⁺ transport has not been studied in detail. Several lung pathogens have been shown to inhibit Na⁺ transport by respiratory epithelia *in vitro*. *Mycoplasma pulmonis* inhibits amiloride-sensitive Na⁺ absorption and cholinergic-stimulated Cl⁻ secretion by C57BL/6 mouse tracheal epithelial cells (45). Similarly, *Pseudomonas aeruginosa* rhamnolipids inhibit amiloride-sensitive Na⁺ transport by ovine tracheal epithelium (26), while the hemolysin blocks active Na⁺ uptake and Cl⁻ secretion by canine bronchial epithelium (71). *Mycobacterium tuberculosis* (77), pneumotropic, but not neurotropic, influenza A virus (42), and Sendai virus (43) have also been shown to inhibit ENaC activity *in vitro*. Influenza A virus rapidly (within 60 minutes of infection) inhibits amiloride-sensitive Na⁺ transport by mouse tracheal epithelial cells. This inhibition is mediated by binding of viral hemagglutinin to cell surface sialic acid moieties, and subsequent activation of phospholipase C and PKC.

Interestingly, the inhibitory effects of pathogens on ENaC found *in vitro* have not always been found *in vivo*. For example, in rats with *P. aeruginosa* pneumonia, alveolar fluid clearance (AFC), which is a functional index of ENaC function, increased 24 hours after infection, and this increase, which was inhibited by amiloride, was at least partially mediated by TNF- α (63). Similarly, instillation of *Escherichia coli* endotoxin into the lungs of rats resulted in a significant increase in AFC at 24 and 40 hours (25). Whether such increases in AFC have detrimental pathophysiological consequences, or whether they are the result of sublethal injury to the alveolar epithelium resulting in its repopulation with increased numbers of ATII cells, remains to be determined. Nev-

ertheless, some pulmonary pathogens may in contrast induce hypoxemia as a result of inhibition of AFC. For example, we recently reported that replicating respiratory syncytial virus (RSV) reduces the AFC of the bronchoalveolar epithelium *in vivo* (Fig 1), without inducing detectable epithelial cell death or an increase in alveolar permeability to albumin (17). Interestingly, we found that RSV-mediated inhibition of AFC was not related to viral loads per se: instead it was mediated by uridine triphosphate (UTP), acting in autocrine fashion on P2YR on bronchoalveolar epithelial cells. Specifically, we found increased levels of UTP in the bronchoalveolar lavage fluid of Balb/c mice 2 days following RSV infection (Fig 2). Moreover, reduced AFC was associated with increased lung water content, and peripheral hypoxemia (16). Addition of apyrase, which degrades both ATP and UTP, or XAMR0721 (a P2Y inhibitor) in the instillate prevented the decrease of AFC (17). Finally, UTP instilled in the alveolar space of Balb/c mice decreased AFC (Fig 3). Reduced AFC may result in formation of an increased volume of fluid mucus, airway congestion, and rhinorrhea, all features of severe RSV disease.




Figure 1. Intranasal infection of BALB/c mice with RSV results in significant inhibition of alveolar fluid clearance (AFC) at days 2 and 4 after infection. Mice were infected with 2×10^6 plaque forming units of RSV, suspended in 100 μ l of buffer, intranasally as previously described (17). Alveolar fluid clearance (lower panel; expressed as % of instilled fluid per 30 min) was measured across anesthetized, ventilated mice, with normal oxygenation and acid-base balance. $n = 6-23$ per group, as previously described (17). Mock infection had no effect on AFC. AFC was inhibited by 43% at day 2 and by 26% at day 4. RSV titers in lung tissues (upper panel; expressed as the log of RSV PFUs per gr lung tissue) peaked at 4 days post infection and then decreased. Threshold of detection is 1 log. Notice the lack of correlation between RSV titers and AFC. Values are means \pm SE. * $p < 0.005$, compared with uninfected mice. Modified from ref 17.




Figure 2. RSV infection increases UTP levels in the BAL of Balb/c mice. Mice were infected with RSV as described in the legend of Figure 1. After 2 days, they were sacrificed and their lungs were lavaged. Endogenous nucleotidases in BAL fluid were heat denatured (100°C, 3 minutes) and UTP content was measured using the UDP-glucose pyrophosphorylase as previously described (16). Numbers are means \pm 1 SEM; * $p < 0.005$ compared to either uninstilled or mock instilled mice. Labels as follows: Un = Uninstilled mice; Mock = Mock infected mice; RSV = infected with 2×10^6 plaque forming units of RSV. Numbers in bars indicate numbers of mice in each group.

ENaC modulation by purinergic nucleotides

Purinergic 5'-nucleotides are known modulators of ENaC activity in respiratory epithelial cells. Relatively large amounts of adenosine triphosphate (ATP) and UTP are released by human respiratory epithelial cells *in vitro*, although the underlying pathway for nucleotide release remains undefined (30; 46). Released ATP is rapidly metabolized to a mixture of ADP, AMP, and adenosine. ATP, its metabolites, and UTP each have inhibitory effects on ENaC, mediated via interaction with purinergic receptors expressed on respiratory epithelial cells (11; 40). Both ATP and UTP are known to inhibit respiratory epithelial Na^+ absorption *in vitro* (32; 33; 35; 50), via interaction with P2Y purinoceptors (P2YR). *In vivo*, UTP administered at pharmacologic doses (100 μM) to human subjects has also been shown to induce Cl^- secretion by nasal epithelium (41) and, when given by aerosol, to promote mucociliary clearance, although, interestingly, in the presence of amiloride, it also induced mild hypoxemia (60).




Figure 3. Instillation of UTP in the alveolar space of Balb/c mice decreases AFC. To confirm that UTP alone can recapitulate the inhibitory effects of RSV on alveolar fluid clearance, we instilled 5% BSA (the standard instillate for the measurement of AFC) containing ten-fold dilutions of UTP into the lungs of normal mice and determined AFC 30 min later. Shown values are means \pm 1 SEM (n 3-4 per group). Final doses of UTP (from 1mM to 10 nM) had a significant inhibitory effect on AFC, but 1 nM UTP had no effect. 1 mM and 100 μ M UTP induced significantly greater inhibition of AFC than that caused by RSV (62% and 70%, respectively), while doses from 1 μ M to 10 nM caused inhibition similar to that induced by infection with RSV for 2 or 4 days (42-36%). Modified from ref. 17.

Protein kinase C as a central regulator of ENaC function?

Until recently, the mechanism by which nucleotide binding to P2YR might induce reduced ENaC activity has remained unclear. While downstream signaling events mediating ENaC downregulation have not yet been fully defined, it is known that P2YR are G-protein-coupled, and act via the inositol phosphate pathway to stimulate calcium release from intracellular stores, but can also act via multiple secondary signal transduction pathways including protein kinase C (PKC) (11). Activation of PKC has been shown to reduce ENaC activity and modify its subunit composition, although the isoforms of PKC involved have not been defined. Inhibition of PKC rapidly increased P_o and appearance of new channels in patches of A6 cells (47). In contrast, stimulation of PKC inhibited whole-cell currents in *Xenopus* oocytes (2). Likewise, PKC activation decreased expression of both β and γ , but not α ENaC subunit proteins in A6 cells by 3h and 14h, respectively, and also resulted in a decrease in transepithelial Na^+ reabsorption (70).

Recent data indicates that P2YR-mediated ENaC downregulation may also involve activation of the ubiquitin-proteasome pathway, which is an important regulator of ENaC function. The half-life of ENaC in mammalian cell membranes is short (less than 1 hour). ENaC is ubiquitinated *in vivo* on the α and γ , but not β subunits (69). Inhibition of ubiquitination or the proteasome results in increased channel activity, due to an increase in the number of channels present at the plasma membrane (49). Ubiquitination (ATP-dependent serial addition of ubiquitin monomers to lysine residues on proteins), which targets proteins for rapid degradation by the proteasome, is catalyzed by the sequential action of ubiquitin-activating, ubiquitin-conjugating, and ubiquitin protein ligase enzymes (29). Neural precursor cell-expressed developmentally down-regulated protein 4 (Nedd4) is the ubiquitin-protein ligase required for ubiquitination of ENaC (69). Nedd4 directly regulates basal ENaC activity by modulating channel stability at the cell surface. In the lung, Nedd4 is mainly expressed in the epithelia lining the airways and in the distal respiratory epithelium, a pattern of expression similar to that of ENaC (8). Interestingly, the interaction between ENaC and Nedd4 is disrupted in Liddle Syndrome, a hereditary form of salt-sensitive hypertension (1). Liddle syndrome mutations in the β ENaC cytoplasmic domain disrupt the association of Nedd4 with the C-terminus of β ENaC. As a result, ENaC has a longer half-life in the plasma membrane and is less efficiently internalized and degraded. This leads to increased amiloride-sensitive current at the apical membrane and increased salt absorption.

The link between PKC and the ubiquitin-proteasome pathway has just recently been made clear. In A6 cells, PKC has been shown to activate the mitogen-activated protein (MAP) kinase Raf-1, and the MAP kinase kinases MAPK/ERK (MEK) 1 and 2. Activation of MEK 1 and 2 was shown to enhance phosphorylation of β and γ , but not α ENaC (67). This phosphorylation event facilitates binding of Nedd4-2 to ENaC, which may then promote ENaC internalization and removal from the cell surface (69). Therefore, purinergic stimulation and PKC activation may decrease ENaC function both through altered ENaC phosphorylation and altered ENaC degradation.

Inflammatory mediators of ENaC dysfunction in pulmonary disease

Reactive oxygen/nitrogen species (RONS), such as the free radicals nitric oxide (\bullet NO) and nitric dioxide (\bullet NO₂) as well as peroxynitrite anions (ONOO⁻), are known to inhibit the activity of both ENaC (31) and the AII cell Na⁺/K⁺ ATPase (72) *in vitro*, via both cGMP-dependent and cGMP-independent mechanisms. In pulmonary inflammatory disease, increased levels of RONS may directly modify ion transporters, disrupt their association with chaperone or structural proteins (such as actin), or alter signal transduction pathways, all of which may result in impaired Na⁺ absorption across the alveolar epithelium. Nitrotyrosine (the stable by-product of \bullet NO₂ reaction with tyrosine residues in proteins (3)) has been detected in the lungs of patients with acute lung injury (44) and those with hantavirus cardiopulmonary syndrome (HCPS) (18). Likewise, both nitrotyrosine and large amounts of nitrate, the stable by-product of peroxynitrite and nitrogen dioxide, have been found in the lavage fluids of patients with acute lung injury and the plasma of hantavirus cardiopulmonary syndrome cases (18). These find-

ings indicate that reactive oxygen-nitrogen species are produced in the lungs of patients with inflammatory disease, and may contribute to its pathogenesis. In a recent study, Modelska et al. (56) showed that absorption of isotonic fluid, secondary to Na^+ absorption across the alveolar space, was inhibited followed prolonged hemorrhagic shock. Moreover, instillation of aminoguanidine, a nitric oxide synthase inhibitor, restored fluid absorption to normal levels. Thus, increased production of reactive oxygen-nitrogen species by lung epithelial or inflammatory cells may modify molecules required for Na^+ transport across the alveolar epithelium.

Finally, it should also be noted that certain proinflammatory cytokines have also been shown to directly alter Na^+ transport by respiratory epithelial cells *in vitro*. Specifically, Na^+ transport is inhibited by $\text{IFN-}\gamma$ (23), and IL-4 (24), while $\text{TNF-}\alpha$ has been shown to both increase (22; 63) and reduce (15) Na^+ transport, *in vivo*.

Effect of β -adrenergic agonists on ENaC function

β -adrenergic receptor agonists (β -agonists) have been shown to improve AFC in animal models of lung injury in which AFC is impaired, by increasing the activity of both epithelial Na^+ channels and Na^+ , K^+ ATPase (reviewed in (58)). β -agonist prophylaxis has also been shown to be of value in reducing the incidence of high altitude pulmonary edema (itself a consequence of impaired AFC secondary to hypoxia at high altitude) in susceptible mountaineers (66), and intravenous salbutamol treatment can reduce extravascular lung water in patients with acute lung injury (61). Because of such encouraging findings, the National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Network is planning to conduct a large, multicenter, prospective clinical trial to test the potential efficacy of the aerosolized β -agonist albuterol in ventilated patients with ARDS (74).

Stimulatory effects of β -agonists on AFC have been shown to be mediated via activation of adenylyl cyclase, which generates cAMP and thereby stimulates cAMP-dependent protein kinase production (protein kinase A; reviewed in (37)). PKA phosphorylates cytoskeletal proteins and promotes both exocytosis to the cell membrane and direct phosphorylation of ENaC β and γ subunits (5). β -agonists also increase the expression of ENaC α -subunit mRNA and protein (55), phosphorylation-dependent translocation of Na^+ , K^+ ATPase pumps from intracellular pools to the basolateral membrane of epithelial cells (6), and apical Cl^- flux through the cystic fibrosis transmembrane conductance regulator (CFTR) (59). However, while it appears that functional β -AR are essential for adaptation to pulmonary edema, it remains unclear whether they are required for maintenance of alveolar fluid balance in the normal lung (58).

Interestingly, several respiratory tract viral pathogens have been shown to modulate β -adrenergic receptor agonist function. Tracheal smooth muscle from influenza virus-infected mice has reduced sensitivity to β -agonists and forskolin *ex vivo* (28), and airway segments taken from ovalbumin-sensitized guinea pigs exhibit impaired bronchodilator responses following infection with parainfluenza 3 virus (9). Likewise, human airway smooth muscle tissue exhibits reduced responsiveness to β -agonists, associated with increased $\text{G}\alpha_i$ expression, following *in vitro* infection with rhinovirus (27) and RSV (57). Finally, we have recently found that RSV induces heterologous desensitiza-

tion of bronchoalveolar epithelial β -AR in vivo (Ian Davis, unpublished observations). These findings have important implications for dysregulation of other β -agonist-mediated responses in respiratory epithelium and airway smooth muscle following viral infection: β -agonists are known to promote mucociliary clearance and fluid secretion by submucosal glands, may have anti-inflammatory effects, and are widely used as bronchodilators (reviewed in (65)).

CONCLUSIONS

Na⁺ transport in the distal lung is required for normal lung function. Defective Na⁺ absorption may contribute to the pathogenesis of acute and chronic lung disease. As the molecular mechanisms of lung injury and disease are better characterized, we may better understand the contribution of ENaC function to pulmonary disease. The demonstration that RONS released by activated alveolar macrophages down regulate the activity of alveolar epithelial cell Na⁺ channels (14) provides an example of how mediators of lung injury could influence Na⁺ absorption during the progression of pneumonia or ARDS. Manipulating ENaC function may provide new treatments for both ARDS and pulmonary infectious diseases. For example, strategies that inhibit UTP-P2YR interaction can now be evaluated as therapeutics for RSV pneumonitis, a condition for which specific antiviral drugs are sadly lacking. Identification of additional targets for regulating ENaC expression and function in the lung may provide further opportunities for clinicians to target Na⁺ absorption in the lung. Moreover, by studying Na⁺ channel physiology in the context of human lung disease, we may learn more about the basic physiology of distal lung transport.

ABBREVIATIONS

AFC = alveolar fluid clearance; AII = alveolar type II cells; ENaC = epithelial sodium channels; RSV = respiratory syncytial virus; UTP = urine triphosphate; RONS = reactive oxygen-nitrogen

ACKNOWLEDGEMENTS

Drs. Davis and Matalon are supported by NIH grants HL31197, HL51173, and RR17626. We like to thank Ms. Terese Potter for excellent editorial assistance.

REFERENCES

1. Abriel H, Loffing J, Rebhun JF, Pratt JH, Schild L, Horisberger JD, Rotin D and Staub O. Defective regulation of the epithelial Na⁺ channel by Nedd4 in Liddle's

- syndrome. *J Clin Invest* 103: 667-673, 1999.
2. Awayda MS, Ismailov II, Berdiev BK, Fuller CM and Benos DJ. Protein kinase regulation of a cloned epithelial Na⁺ channel. *J Gen Physiol* 108: 49-65, 1996.
 3. Beckman JS and Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. [Review] [109 refs]. *American Journal of Physiology* 271: C1424-C1437, 1996.
 4. Benos DJ. Amiloride: a molecular probe of sodium transport in tissues and cells. *Am J Physiol* 242: C131-45, 1982.
 5. Berdiev BK, Prat AG, Cantiello HF, Ausiello DA, Fuller CM, Jovov B, Benos DJ and Ismailov II. Regulation of epithelial sodium channels by short actin filaments. *J Biol Chem* 271: 17704-17710, 1996.
 6. Bertorello AM, Ridge KM, Chibalin AV, Katz AI and Sznajder JI. Isoproterenol increases Na⁺-K⁺-ATPase activity by membrane insertion of alpha-subunits in lung alveolar cells. *American Journal of Physiology* 276: L20-L27, 1999.
 7. Borok Z, Liebler JM, Lubman RL, Foster MJ, Zhou B, Li X, Zabski SM, Kim KJ and Crandall ED. Na transport proteins are expressed by rat alveolar epithelial type I cells. *Am J Physiol Lung Cell Mol Physiol* 282: L599-L608, 2002.
 8. Brochard L and Lemaire F. Tidal volume, positive end-expiratory pressure, and mortality in acute respiratory distress syndrome [editorial; comment]. *Crit Care Med* 27: 1661-1663, 1999.
 9. Buckner CK, Clayton DE, in-Shoka AA, Busse WW, Dick EC and Shult P. Parainfluenza 3 infection blocks the ability of a beta adrenergic receptor agonist to inhibit antigen-induced contraction of guinea pig isolated airway smooth muscle. *J Clin Invest* 67: 376-384, 1981.
 10. Burch LH, Talbot CR, Knowles MR, Canessa CM, Rossier BC and Boucher RC. Relative expression of the human epithelial Na⁺ channel subunits in normal and cystic fibrosis airways. *Am J Physiol* 269: C511-C518, 1995.
 11. Burnstock G and Williams M. P2 purinergic receptors: modulation of cell function and therapeutic potential. *J Pharmacol Exp Ther* 295: 862-869, 2000.
 12. Canessa CM, Schild L, Buell G, Thorens B, Gautschi I, Horisberger JD and Rossier BC. Amiloride-sensitive epithelial Na⁺ channel is made of three homologous subunits. *Nature* 367: 463-467, 1994.
 13. Comellas AP, Pesce LM, Azzam Z, Saldias FJ and Sznajder JI. Scorpion venom decreases lung liquid clearance in rats. *Am J Respir Crit Care Med* 167: 1064-1067, 2003.
 14. Compeau CG, Rotstein OD, Tohda H, Marunaka Y, Rafii B, Slutsky AS and O'Brodovich H. Endotoxin-stimulated alveolar macrophages impair lung epithelial Na⁺ transport by an L-Arg-dependent mechanism. *Am J Physiol* 266: C1330-41, 1994.
 15. Dagenais A, Frechette R, Yamagata Y, Yamagata T, Carmel JF, Clermont ME, Brochiero E, Masse C and Berthiaume Y. Downregulation of ENaC Activity and Expression by TNF-alpha In Alveolar Epithelial Cells. *Am J Physiol Lung Cell Mol Physiol* .: 2003.
 16. Davis IC, Lazarowski ER, Hickman-Davis JM, Fortenberry JA, Chen FP, Zhao X, Sorscher E, Graves LM, Sullender WM and Matalon S. Leflunomide prevents alveolar fluid clearance inhibition by respiratory syncytial virus. *Am J Respir Crit Care Med* 173: 673-682, 2005.
 17. Davis IC, Sullender WM, Hickman-Davis JM, Lindsey JR and Matalon S. Nucleotide-mediated inhibition of alveolar fluid clearance in BALB/c mice after respiratory syncytial virus infection. *Am J Physiol Lung Cell Mol Physiol* 286: L112-L120,

- 2004.
18. Davis IC, Zajac AJ, Nolte KB, Botten J, Hjelle B and Matalon S. Elevated generation of reactive oxygen/nitrogen species in hantavirus cardiopulmonary syndrome. *J Virol* 76: 8347-8359, 2002.
 19. Dobbs LG. Isolation and culture of alveolar type II cells. *Am J Physiol* 258: L134-47, 1990.
 20. Factor P, Senne C, Dumasius V, Ridge K, Jaffe HA, Uhal B, Gao Z and Sznajder JI. Overexpression of the Na⁺,K⁺-ATPase alpha 1 subunit increases Na⁺,K⁺-ATPase function in A549 cells. *Am J Respir Cell Mol Biol* 18: 741-749, 1998.
 21. Firsov D, Gautschi I, Merillat AM, Rossier BC and Schild L. The heterotetrameric architecture of the epithelial sodium channel (ENaC). *EMBO J* 17: 344-352, 1998.
 22. Fukuda N, Jayr C, Lazrak A, Wang Y, Lucas R, Matalon S and Matthay MA. Mechanisms of TNF-alpha stimulation of amiloride-sensitive sodium transport across alveolar epithelium. *Am J Physiol Lung Cell Mol Physiol* 280: L1258-L1265, 2001.
 23. Galiotta LJ, Folli C, Marchetti C, Romano L, Carpani D, Conese M and Zegarra-Moran O. Modification of transepithelial ion transport in human cultured bronchial epithelial cells by interferon-gamma. *Am J Physiol Lung Cell Mol Physiol* 278: L1186-L1194, 2000.
 24. Galiotta LJ, Pagesy P, Folli C, Caci E, Romio L, Costes B, Nicolis E, Cabrini G, Goossens M, Ravazzolo R and Zegarra-Moran O. IL-4 is a potent modulator of ion transport in the human bronchial epithelium in vitro. *J Immunol* 168: 839-845, 2002.
 25. Garat C, Rezaiguia S, Meignan M, D'Ortho MP, Harf A, Matthay MA and Jayr C. Alveolar endotoxin increases alveolar liquid clearance in rats. *J Appl Physiol* 79: 2021-2028, 1995.
 26. Graham A, Steel DM, Wilson R, Cole PJ, Alton EW and Geddes DM. Effects of purified *Pseudomonas* rhamnolipids on bioelectric properties of sheep tracheal epithelium. *Exp Lung Res* 19: 77-89, 1993.
 27. Grunstein MM, Hakonarson H, Whelan R, Yu Z, Grunstein JS and Chuang S. Rhinovirus elicits proasthmatic changes in airway responsiveness independently of viral infection. *J Allergy Clin Immunol* 108: 997-1004, 2001.
 28. Henry PJ, Rigby PJ, Mackenzie JS and Goldie RG. Effect of respiratory tract viral infection on murine airway beta-adrenoceptor function, distribution and density. *Br J Pharmacol* 104: 914-921, 1991.
 29. Hochstrasser M. Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. *Curr Opin Cell Biol* 7: 215-223, 1995.
 30. Homolya L, Steinberg TH and Boucher RC. Cell to cell communication in response to mechanical stress via bilateral release of ATP and UTP in polarized epithelia. *J Cell Biol* 150: 1349-1360, 2000.
 31. Hu P, Ischiropoulos H, Beckman JS and Matalon S. Peroxynitrite inhibition of oxygen consumption and sodium transport in alveolar type II cells. *Am J Physiol* 266: L628-34, 1994.
 32. Inglis SK, Collett A, McAlroy HL, Wilson SM and Olver RE. Effect of luminal nucleotides on Cl⁻ secretion and Na⁺ absorption in distal bronchi. *Pflugers Arch* 438: 621-627, 1999.
 33. Inglis SK, Olver RE and Wilson SM. Differential effects of UTP and ATP on ion transport in porcine tracheal epithelium. *Br J Pharmacol* 130: 367-374, 2000.
 34. Ismailov II, Awayda MS, Jovov B, Berdiev BK, Fuller CM, Dedman JR, Kaetzel M and Benos DJ. Regulation of epithelial sodium channels by the cystic fibrosis transmembrane conductance regulator. *J Biol Chem* 271: 4725-4732, 1996.

35. Iwase N, Sasaki T, Shimura S, Yamamoto M, Suzuki S and Shirato K. ATP-induced Cl⁻ secretion with suppressed Na⁺ absorption in rabbit tracheal epithelium. *Respir Physiol* 107: 173-180, 1997.
36. Jain L, Chen XJ, Ramosevac S, Brown LA and Eaton DC. Expression of highly selective sodium channels in alveolar type II cells is determined by culture conditions. *Am J Physiol Lung Cell Mol Physiol* 280: L646-L658, 2001.
37. Johnson M. Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. *J Allergy Clin Immunol* 117: 18-24, 2006.
38. Johnson MD, Widdicombe JH, Allen L, Barbry P and Dobbs LG. Alveolar epithelial type I cells contain transport proteins and transport sodium, supporting an active role for type I cells in regulation of lung liquid homeostasis. *Proc Natl Acad Sci U S A* 99: 1966-1971, 2002.
39. Kerem E, Bistritzer T, Hanukoglu A, Hofmann T, Zhou Z, Bennett W, MacLaughlin E, Barker P, Nash M, Quittell L, Boucher R and Knowles MR. Pulmonary epithelial sodium-channel dysfunction and excess airway liquid in pseudohypoaldosteronism. *N Engl J Med* 341: 156-162, 1999.
40. Kishore BK, Ginns SM, Krane CM, Nielsen S and Knepper MA. Cellular localization of P2Y(2) purinoceptor in rat renal inner medulla and lung. *Am J Physiol Renal Physiol* 278: F43-F51, 2000.
41. Knowles MR, Clarke LL and Boucher RC. Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. *N Engl J Med* 325: 533-538, 1991.
42. Kunzelmann K, Beesley AH, King NJ, Karupiah G, Young JA and Cook DI. From the cover: influenza virus inhibits amiloride-sensitive Na⁺ channels in respiratory epithelia. *Proc Natl Acad Sci U S A* 97: 10282-10287, 2000.
43. Kunzelmann K, Konig J, Sun J, Markovich D, King NJ, Karupiah G, Young JA and Cook DI. Acute effects of parainfluenza virus on epithelial electrolyte transport. *J Biol Chem* 279: 48760-48766, 2004.
44. Lamb RA, Zebedee SL and Richardson CD. Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. *Cell* 40: 627-633, 1985.
45. Lambert LC, Trummell HQ, Singh A, Cassell GH and Bridges RJ. *Mycoplasma pulmonis* inhibits electrogenic ion transport across murine tracheal epithelial cell monolayers. *Infect Immun* 66: 272-279, 1998.
46. Lazarowski ER and Boucher RC. UTP as an extracellular signaling molecule. *News Physiol Sci* 16:1-5.: 1-5, 2001.
47. Ling BN and Eaton DC. Effects of luminal Na⁺ on single Na⁺ channels in A6 cells, a regulatory role for protein kinase C. *Am J Physiol* 256: F1094-F1103, 1989.
48. Malhotra A and Krilov LR. Influenza and respiratory syncytial virus. Update on infection, management, and prevention. *Pediatr Clin North Am* 47: 353-vii, 2000.
49. Malik B, Schlanger L, Al Khalili O, Bao HF, Yue G, Price SR, Mitch WE and Eaton DC. Enac degradation in A6 cells by the ubiquitin-proteasome proteolytic pathway. *J Biol Chem* %20;276: 12903-12910, 2001.
50. Mall M, Wissner A, Gonska T, Calenborn D, Kuehr J, Brandis M and Kunzelmann K. Inhibition of amiloride-sensitive epithelial Na⁽⁺⁾ absorption by extracellular nucleotides in human normal and cystic fibrosis airways. *Am J Respir Cell Mol Biol* 23: 755-761, 2000.
51. Matalon S, Benos DJ and Jackson RM. Biophysical and molecular properties of amiloride-inhibitable Na⁺ channels in alveolar epithelial cells. *Am J Physiol* 271: L1-22, 1996.
52. Matalon S and Davis IC. Vectorial sodium transport across the mammalian alveolar

- epithelium: it occurs but through which cells? *Circ Res* 92: 348-349, 2003.
53. Matalon S and O'Brodovich H. Sodium channels in alveolar epithelial cells: molecular characterization, biophysical properties, and physiological significance. *Annu Rev Physiol* 61: 627-661, 1999.
 54. Matthay MA and Wiener-Kronish JP. Intact epithelial barrier function is critical for the resolution of alveolar edema in humans. *Am Rev Respir Dis* 142: 1250-1257, 1990.
 55. Minakata Y, Suzuki S, Grygorczyk C, Dagenais A and Berthiaume Y. Impact of beta-adrenergic agonist on Na⁺ channel and Na⁺-K⁺-ATPase expression in alveolar type II cells. *American Journal of Physiology* 275: L414-L422, 1998.
 56. Modelska K, Matthay MA, McElroy MC and Pittet JF. Upregulation of alveolar liquid clearance after fluid resuscitation for hemorrhagic shock in rats. *Am J Physiol* 273: L305-L314, 1997.
 57. Moore PE, Cunningham G, Calder MM, Dematteo AD, Jr., Peeples ME, Summar ML and Peebles RS, Jr. Respiratory syncytial virus infection reduces beta2-adrenergic responses in human airway smooth muscle. *Am J Respir Cell Mol Biol* 35: 559-564, 2006.
 58. Mutlu GM, Koch WJ and Factor P. Alveolar epithelial {beta}2-adrenergic receptors: their role in regulation of alveolar active sodium transport. *Am J Respir Crit Care Med* 170: 1270-1275, 2004.
 59. O'Grady SM, Jiang X and Ingbar DH. Cl-channel activation is necessary for stimulation of Na transport in adult alveolar epithelial cells. *Am J Physiol Lung Cell Mol Physiol* 278: L239-L244, 2000.
 60. Olivier KN, Bennett WD, Hohneker KW, Zeman KL, Edwards LJ, Boucher RC and Knowles MR. Acute safety and effects on mucociliary clearance of aerosolized uridine 5'-triphosphate +/- amiloride in normal human adults. *Am J Respir Crit Care Med* 154: 217-223, 1996.
 61. Perkins GD, McAuley DF, Thickett DR and Gao F. The beta-agonist lung injury trial (BALTI): a randomized placebo-controlled clinical trial. *Am J Respir Crit Care Med* 173: 281-287, 2006.
 62. Planes C, Blot-Chaubaud M, Matthay MA, Couette S, Uchida T and Clerici C. Hypoxia and beta 2-agonists regulate cell surface expression of the epithelial sodium channel in native alveolar epithelial cells. *J Biol Chem* 277: 47318-47324, 2002.
 63. Rezaiguia S, Garat C, Delclaux C, Meignan M, Fleury J, Legrand P, Matthay MA and Jayr C. Acute bacterial pneumonia in rats increases alveolar epithelial fluid clearance by a tumor necrosis factor-alpha-dependent mechanism. *J Clin Invest* 99: 325-335, 1997.
 64. Rotin D, Bar-Sagi D, O'Brodovich H, Merilainen J, Lehto VP, Canessa CM, Rossier BC and Downey GP. An SH3 binding region in the epithelial Na⁺ channel (alpha rENaC) mediates its localization at the apical membrane. *EMBO J* 13: 4440-4450, 1994.
 65. Salathe M. Effects of beta-agonists on airway epithelial cells. *J Allergy Clin Immunol* 110: S275-S281, 2002.
 66. Sartori C, Allemann Y, Duplain H, Lepori M, Egli M, Lipp E, Hutter D, Turini P, Hugli O, Cook S, Nicod P and Scherrer U. Salmeterol for the prevention of high-altitude pulmonary edema. *N Engl J Med* 346: 1631-1636, 2002.
 67. Shimkets RA, Lifton R and Canessa CM. In vivo phosphorylation of the epithelial sodium channel. *Proc Natl Acad Sci U S A* 95: 3301-3305, 1998.
 68. Snyder PM, Cheng C, Prince LS, Rogers JC and Welsh MJ. Electrophysiological and biochemical evidence that DEG/ENaC cation channels are composed of nine subunits. *J Biol Chem* 273: 681-684, 1998.

69. Staub O, Abriel H, Plant P, Ishikawa T, Kanelis V, Saleki R, Horisberger JD, Schild L and Rotin D. Regulation of the epithelial Na⁺ channel by Nedd4 and ubiquitination. *Kidney Int* 57: 809-815, 2000.
70. Stockand JD, Bao HF, Schenck J, Malik B, Middleton P, Schlanger LE and Eaton DC. Differential effects of protein kinase C on the levels of epithelial Na⁺ channel subunit proteins [In Process Citation]. *J Biol Chem* 275: 25760-25765, 2000.
71. Stutts MJ, Schwab JH, Chen MG, Knowles MR and Boucher RC. Effects of *Pseudomonas aeruginosa* on bronchial epithelial ion transport. *Am Rev Respir Dis* 134: 17-21, 1986.
72. Sznajder JI, Olivera W, Ridge KM, Rutschman DH, Olivera WG and Ridge KM. Mechanisms of lung liquid clearance during hyperoxia in isolated rat lungs. *Am J Respir Crit Care Med* 151: 1519-1525, 1995.
73. Venkatesh VC and Katzberg HD. Glucocorticoid regulation of epithelial sodium channel genes in human fetal lung. *Am J Physiol* 273: L227-L233, 1997.
74. Wiener-Kronish JP and Matthay MA. Beta-2-agonist treatment as a potential therapy for acute inhalational lung injury. *Crit Care Med* 34: 1841-1842, 2006.
75. Yue G and Matalon S. Mechanisms and sequelae of increased alveolar fluid clearance in hyperoxic rats. *Am J Physiol* 272: L407-12, 1997.
76. Yue G, Shoemaker RL and Matalon S. Regulation of low-amiloride-affinity sodium channels in alveolar type II cells. *Am J Physiol* 267: L94-100, 1994.
77. Zhang M, Kim KJ, Iyer D, Lin Y, Belisle J, McEnery K, Crandall ED and Barnes PF. Effects of *Mycobacterium tuberculosis* on the bioelectric properties of the alveolar epithelium. *Infect Immun* 65: 692-698, 1997.
78. Zhu S, Ware LB, Geiser, T, Matthay, MA and Matalon S. Increased levels of nitrate and surfactant protein A nitration in the pulmonary edema fluid of patients with acute lung injury. *Am J Crit Care Med* 163: 166-172, 2001.